A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

The transaction has been unanimously approved by the Board of Directors ... The Anaren, Inc. logo is available at About AML: AML is a designer, manufacturer, and marketer of microelectronic ...

VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline ...

TIBSOVO ® is the First and Only Therapy Approved for Newly Diagnosed AML Patients with an IDH1 Mutation who are Ineligible for Intensive Chemotherapy – – sNDA Approval Based on 28 Newly ...

The approval of Tibsovo was based on an open-label, single-arm, multicenter clinical trial (Study AG120-C-001) involving 174 patients with relapsed or refractory AML with an IDH1 miutation.

A considerable proportion of the recently approved and pipeline AML treatments are mutationally targeted, and despite their smaller target patient populations, are anticipated to contribute ...

Treosulfan plus fludarabine is approved for alloHSCT in patients with AML or MDS aged 1 year and older. Clinical trial results showed improved overall survival with treosulfan compared to busulfan.

The treatment was evaluated in the Phase 2 BRIGHT 1003 trial which randomized newly-diagnosed AML patients to receive Daurismo + LDAC (N=77) or LDAC alone (N=38) until disease progression or ...

The U.S. Food and Drug Administration today approved Daurismo (glasdegib ... for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or ...